|
|
 |
|
Viewing report
|
|
|
|
U.S. HIV/AIDS Therapeutic Markets
Frost & Sullivan, Sep 1999
This report covers the markets for major HIV/AIDS drug therapies, including protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs). It also examines a range of emerging drugs and therapies. By evaluating challenges and presenting forecasts both by product and product type, this report offers its users a comprehensive guide to the HIV/AIDS drug markets. This report, which monitors industry changes and analyzes competitive strategies, can help your firm develop a winning plan of action. From Frost & Sullivan.
Customers who bought this item also bought
European HIV/AIDS Drug Markets
Forecast Insight: HIV - Increasing dominance of fixed dose combinations raises bar for single agents
Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity
HIV/AIDS Testing - Global Strategic Business Report
Analysis of the Anticoagulant Market
Epidemiology: Peripheral Neuropathic Pain - A common co-morbidity for HIV, diabetes, and herpes zoster
R&D Trends: HIV - An active pipeline faces fierce competition in the HIV market
HIV/AIDS Testing - World Review
Molecular Diagnostics - Technologies, Markets and Companies
Opportunities Assessment for Hepatitis B Therapeutics Market in Indonesia
|
|
|
|
